40372-00-7
Chemical Structure
Taribavirin hydrochloride
- CAS No.: 40372-00-7
- Formula:C8H14ClN5O4
- Molecular Weight:279.68
IUPAC Name: 1-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1H-1,2,4-triazole-3-carboximidamide hydrochloride
InChIKey: PIGYMBULXKLTCJ-UHSSARMYSA-N
SMILES: N=C(C1=NN([C@H]2[C@@H]([C@@H]([C@@H](CO)O2)O)O)C=N1)N.Cl
Biological Activity: Taribavirin hydrochloride is an orally active inosine monophosphate dehydrogenase inhibitor, has activity against a wide range of viruses, especially the hepatitis C virus and influenza virus. Taribavirin hydrochloride is a Ribavirin proagent, is designed to concentrate within the liver to target HCV-infected hepatocytes while minimizing distribution within red blood cells (RBCs) and the development of hemolytic anemia[2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Taribavirin hydrochloride | 99.89% | Taribavirin hydrochloride is an orally active inosine monophosphate dehydrogenase inhibitor, has activity against a wide range of viruses, especially the hepatitis C virus and influenza virus. Taribavirin hydrochloride is a Ribavirin proagent, is designed to concentrate within the liver to target HCV-infected hepatocytes while minimizing distribution within red blood cells (RBCs) and the development of hemolytic anemia. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Taribavirin hydrochloride (Standard) | ≥98% | Taribavirin hydrochloride (Standard) is the analytical standard of Taribavirin hydrochloride (HY-10545A). This product is intended for research and analytical applications. Taribavirin hydrochloride is an orally active inosine monophosphate dehydrogenase inhibitor, has activity against a wide range of viruses, especially the hepatitis C virus and influenza virus. Taribavirin hydrochloride is a Ribavirin proagent, is designed to concentrate within the liver to target HCV-infected hepatocytes while minimizing distribution within red blood cells (RBCs) and the development of hemolytic anemia. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
